LSTA — LISATA THERAPEUTICS, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 320017 ·
Last close
$3.52
Market Cap
$32.05M
52W High
$5.05
52W Low
$2.75
ADV30
158,569
Next earnings
2026-08-06
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -4,942,000 | -4,489,000 | 14,059,000 | 13,060,000 | 3,387,000 |
| Dec 2025 | 100,000 | — | -3,079,000 | -2,954,000 | 17,744,000 | 15,956,000 | 3,143,000 |
| Sep 2025 | 0 | — | -4,414,000 | -4,249,000 | 21,759,000 | 18,998,000 | 4,640,000 |
| Jun 2025 | 70,000 | — | -4,868,000 | -4,659,000 | 25,160,000 | 16,835,000 | 4,385,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-13,630,000
Investing CF
$5,655,000
Financing CF
$803,000
CapEx
$-28,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.08
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-564,652,000
Inventory
—
Receivables
$0
ST Investments
$0
EBIT TTM
$-18,208,000
Pretax Income TTM
$-17,548,000
Interest Exp TTM
—
Analysts
2
Yahoo Snapshot (yfinance, live)
Total Revenue
$170,000
EBITDA
$-17,199,000
Free Cash Flow
$-8,225,000
Enterprise Value
$18,467,304
Total Cash
$13,060,000
Total Debt
$0
Shares Out
9,106,391
Trailing EPS
$-1.86
Book Value
$1.20
ROE
-91.4%
ROA
-50.3%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 170,000 | -18,209,000 | -16,586,000 | 17,744,000 | 3,143,000 | — | -15,949,000 |
| Dec 2024 | 1,000,000 | -22,409,000 | -19,985,000 | 35,002,000 | 5,685,000 | — | -19,356,000 |
| Dec 2023 | 0 | -25,708,000 | -20,840,000 | 54,694,000 | 6,800,000 | — | -20,032,000 |
| Dec 2022 | 0 | -57,601,000 | -54,225,000 | 73,034,000 | 6,710,000 | — | -21,170,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-6,927,000
OpCashFlow TTM
$0
Assets (Latest)
$35,002,000
Forward EPS
$-1.16
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ATNM | Actinium Pharmaceuticals, Inc. | $32.00M | $1.02 | — |
| SDEV | Stablecoin Development Corp | $32.27M | $1.19 | — |
| BOLD | Boundless Bio, Inc. | $31.45M | $1.40 | — |
| LITS | Lite Strategy, Inc. | $31.28M | $0.92 | — |
| DARE | Dare Bioscience, Inc. | $31.16M | $2.08 | — |
News headlines (Yahoo Finance, 1h cache)
Lisata Therapeutics agrees to Kuva Labs buyout at $4 per share
2026-06-10 13:36 · Yahoo
Lisata Therapeutics Announces Commencement of Tender Offer by Kuva Labs Inc.
2026-06-10 12:00 · Yahoo
Lisata Therapeutics shares up 20% as Kuva Labs acquisition advances
2026-03-09 14:29 · Yahoo
Lisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc.
2026-03-06 23:15 · Yahoo
Lisata Therapeutics Announces Mutual Termination of License Agreement with Qilu Pharmaceutical for Certepetide
2026-01-27 13:00 · Yahoo
Lisata Therapeutics And 2 Other Penny Stocks Worth Watching
2026-01-22 12:04 · Yahoo
How The Evolving Story For Lisata Therapeutics (LSTA) Is Reshaping Its Valuation Outlook
2026-01-22 07:07 · Yahoo
Lisata Therapeutics Enters Into Term Sheet to be Acquired by Kuva Labs for $4.00 Per Share in an All-Cash Tender Offer
2026-01-21 12:00 · Yahoo
LSTA Releases Valuations Report on Level 3 Loans
2025-12-04 14:00 · Yahoo
Lisata Therapeutics Inc (LSTA) Q3 2025 Earnings Call Highlights: Strategic Alliances and Cost ...
2025-11-07 05:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.